1. Alzheimer's disease drug development pipeline: 2017
Jeffrey Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong 
Alzheimer's & Dementia: Translational Research & Clinical Interventions 
Volume 3, Issue 3, Pages (September 2017)
DOI: /j.trci
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1
Agents in clinical trials for the treatment of Alzheimer's disease in 2017 (from clinicaltrials.gov accessed 1/5/2017). Abbreviations: ATP, adenosine triphosphate; BNC, bisnorcymserine; GM-CSF, granulocyte-macrophage colony-stimulating factor; OAA, oxaloacetate; IVIG, intravenous immunoglobulin; SLAT, simvastatin + L-arginine + tetrahydrobiopterin.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, DOI: ( /j.trci )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Mechanisms of action of agents in phase II. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, DOI: ( /j.trci )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Mechanisms of action of agents in phase III. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, DOI: ( /j.trci )
Copyright © 2017 The Authors Terms and Conditions

5. Fig. 4
Illustration of drug mechanism (phase III agents) and the proposed biology of Alzheimer's disease. (A) Amyloid cascade. (B) Downstream pathophysiology. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, DOI: ( /j.trci )
Copyright © 2017 The Authors Terms and Conditions